{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:10:54Z","timestamp":1790255454681,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA167174"],"award-info":[{"award-number":["R01CA167174"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pancreatic ductal adenocarcinoma (PDAC) is characterized by marked desmoplasia and drug resistance due, in part, to poor drug delivery to extravascular tumor tissue. Here, we report that carcinoma-associated fibroblasts (CAFs) induce \u03b25 integrin expression in tumor cells in a TGF-\u03b2 dependent manner, making them an efficient drug delivery target for the tumor-penetrating peptide iRGD. The capacity of iRGD to deliver conjugated and co-injected payloads is markedly suppressed when \u03b25 integrins are knocked out in the tumor cells. Of note, \u03b25 integrin knock-out in tumor cells leads to reduced disease burden and prolonged survival of the mice, demonstrating its contribution to PDAC progression. iRGD significantly potentiates co-injected chemotherapy in KPC mice with high \u03b25 integrin expression and may be a powerful strategy to target an aggressive PDAC subpopulation.<\/jats:p>","DOI":"10.1038\/s41467-021-21858-1","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T11:03:14Z","timestamp":1615287794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Tumor-penetrating therapy for \u03b25 integrin-rich pancreas cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Tatiana","family":"Hurtado de Mendoza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline S.","family":"Mose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Botta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary B.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata R.","family":"Kotamraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall P.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodai","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Miyamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tambet","family":"Teesalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkki","family":"Ruoslahti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Lowy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4946-192X","authenticated-orcid":false,"given":"Kazuki N.","family":"Sugahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"key":"21858_CR1","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-14-1051","volume":"21","author":"CJ Whatcott","year":"2015","unstructured":"Whatcott, C. J. et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin. Cancer Res. 21, 3561\u20133568 (2015).","journal-title":"Clin. Cancer Res."},{"key":"21858_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bjc.2012.569","volume":"108","author":"PP Provenzano","year":"2013","unstructured":"Provenzano, P. P. & Hingorani, S. R. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br. J. Cancer 108, 1\u20138 (2013).","journal-title":"Br. J. Cancer"},{"key":"21858_CR3","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1073\/pnas.1018892108","volume":"108","author":"B Diop-Frimpong","year":"2011","unstructured":"Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y. & Jain, R. K. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl Acad. Sci. USA 108, 2909\u20132914 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21858_CR4","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","volume":"21","author":"PP Provenzano","year":"2012","unstructured":"Provenzano, P. P. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418\u2013429 (2012).","journal-title":"Cancer Cell"},{"key":"21858_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"25","author":"AD Rhim","year":"2014","unstructured":"Rhim, A. D. et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735\u2013747 (2014).","journal-title":"Cancer Cell"},{"key":"21858_CR6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582\u2013598 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"21858_CR7","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrc1877","volume":"6","author":"R Kalluri","year":"2006","unstructured":"Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 6, 392\u2013401 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"21858_CR8","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle, E. & Massague, J. Transforming growth factor-beta signaling in immunity and cancer. Immunity 50, 924\u2013940 (2019).","journal-title":"Immunity"},{"key":"21858_CR9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nrc1208","volume":"3","author":"PM Siegel","year":"2003","unstructured":"Siegel, P. M. & Massague, J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat. Rev. Cancer 3, 807\u2013821 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"21858_CR10","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/bjc.2016.255","volume":"115","author":"C Bellomo","year":"2016","unstructured":"Bellomo, C., Caja, L. & Moustakas, A. Transforming growth factor beta as regulator of cancer stemness and metastasis. Br. J. Cancer 115, 761\u2013769 (2016).","journal-title":"Br. J. Cancer"},{"key":"21858_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","volume":"110","author":"RO Hynes","year":"2002","unstructured":"Hynes, R. O. Integrins: bidirectional, allosteric signaling machines. Cell 110, 673\u2013687 (2002).","journal-title":"Cell"},{"key":"21858_CR12","doi-asserted-by":"publisher","first-page":"36400","DOI":"10.1074\/jbc.M002131200","volume":"275","author":"CF Lai","year":"2000","unstructured":"Lai, C. F. et al. Transforming growth factor-beta up-regulates the beta 5 integrin subunit expression via Sp1 and Smad signaling. J. Biol. Chem. 275, 36400\u201336406 (2000).","journal-title":"J. Biol. Chem."},{"key":"21858_CR13","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1083\/jcb.129.3.853","volume":"129","author":"G Zambruno","year":"1995","unstructured":"Zambruno, G. et al. Transforming growth factor-beta 1 modulates beta 1 and beta 5 integrin receptors and induces the de novo expression of the alpha v beta 6 heterodimer in normal human keratinocytes: implications for wound healing. J. Cell Biol. 129, 853\u2013865 (1995).","journal-title":"J. Cell Biol."},{"key":"21858_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9\u201322 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"21858_CR15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/0092-8674(86)90259-X","volume":"44","author":"E Ruoslahti","year":"1986","unstructured":"Ruoslahti, E. & Pierschbacher, M. D. Arg-Gly-Asp: a versatile cell recognition signal. Cell 44, 517\u2013518 (1986).","journal-title":"Cell"},{"key":"21858_CR16","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1083\/jcb.200304105","volume":"162","author":"JD Hood","year":"2003","unstructured":"Hood, J. D., Frausto, R., Kiosses, W. B., Schwartz, M. A. & Cheresh, D. A. Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J. Cell Biol. 162, 933\u2013943 (2003).","journal-title":"J. Cell Biol."},{"key":"21858_CR17","doi-asserted-by":"publisher","first-page":"5208","DOI":"10.1128\/MCB.20.14.5208-5215.2000","volume":"20","author":"XZ Huang","year":"2000","unstructured":"Huang, X. Z. et al. Fatal bilateral chylothorax in mice lacking the integrin alpha9beta1. Mol. Cell. Biol. 20, 5208\u20135215 (2000).","journal-title":"Mol. Cell. Biol."},{"key":"21858_CR18","doi-asserted-by":"crossref","unstructured":"Uhlen, M. et al. A pathology atlas of the human cancer transcriptome. Science 357, eaan2507 (2017).","DOI":"10.1126\/science.aan2507"},{"key":"21858_CR19","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ccr.2009.10.013","volume":"16","author":"KN Sugahara","year":"2009","unstructured":"Sugahara, K. N. et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16, 510\u2013520 (2009).","journal-title":"Cancer Cell"},{"key":"21858_CR20","doi-asserted-by":"publisher","first-page":"16157","DOI":"10.1073\/pnas.0908201106","volume":"106","author":"T Teesalu","year":"2009","unstructured":"Teesalu, T., Sugahara, K. N., Kotamraju, V. R. & Ruoslahti, E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc. Natl Acad. Sci. USA 106, 16157\u201316162 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21858_CR21","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1172\/JCI92284","volume":"127","author":"X Liu","year":"2017","unstructured":"Liu, X. et al. Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. J. Clin. Investig. 127, 2007\u20132018 (2017).","journal-title":"J. Clin. Investig."},{"key":"21858_CR22","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1101\/gad.1415606","volume":"20","author":"AF Hezel","year":"2006","unstructured":"Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N. & Depinho, R. A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20, 1218\u20131249 (2006).","journal-title":"Genes Dev."},{"key":"21858_CR23","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1158\/1078-0432.CCR-09-2384","volume":"16","author":"WW Tseng","year":"2010","unstructured":"Tseng, W. W. et al. Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host. Clin. Cancer Res. 16, 3684\u20133695 (2010).","journal-title":"Clin. Cancer Res."},{"key":"21858_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/1535-7163.MCT-14-0366","volume":"14","author":"KN Sugahara","year":"2015","unstructured":"Sugahara, K. N. et al. Tumor-penetrating iRGD peptide inhibits metastasis. Mol. Cancer Ther. 14, 120\u2013128 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"21858_CR25","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nmat3982","volume":"13","author":"GB Braun","year":"2014","unstructured":"Braun, G. B. et al. Etchable plasmonic nanoparticle probes to image and quantify cellular internalization. Nat. Mater. 13, 904\u2013911 (2014).","journal-title":"Nat. Mater."},{"key":"21858_CR26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jconrel.2016.04.027","volume":"232","author":"GB Braun","year":"2016","unstructured":"Braun, G. B. et al. Urokinase-controlled tumor penetrating peptide. J. Control. Release 232, 188\u2013195 (2016).","journal-title":"J. Control. Release"},{"key":"21858_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09296-6","volume":"10","author":"N Ding","year":"2019","unstructured":"Ding, N. et al. iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer. Nat. Commun. 10, 1336 (2019).","journal-title":"Nat. Commun."},{"key":"21858_CR28","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1158\/2159-8290.CD-19-0273","volume":"9","author":"G Biffi","year":"2019","unstructured":"Biffi, G. & Tuveson, D. A. A FATal combination: fibroblast-derived lipids and cancer-derived autotaxin promote pancreatic cancer growth. Cancer Discov. 9, 578\u2013580 (2019).","journal-title":"Cancer Discov."},{"key":"21858_CR29","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1038\/sj.onc.1208429","volume":"24","author":"A Eger","year":"2005","unstructured":"Eger, A. et al. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 24, 2375\u20132385 (2005).","journal-title":"Oncogene"},{"key":"21858_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","volume":"134","author":"J Massague","year":"2008","unstructured":"Massague, J. TGFbeta in cancer. Cell 134, 215\u2013230 (2008).","journal-title":"Cell"},{"key":"21858_CR31","doi-asserted-by":"crossref","unstructured":"Adamska, A., Domenichini, A. & Falasca, M. Pancreatic ductal adenocarcinoma: current and evolving therapies. Int. J. Mol. Sci. 18, 1338 (2017).","DOI":"10.3390\/ijms18071338"},{"key":"21858_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469\u2013483 (2005).","journal-title":"Cancer Cell"},{"key":"21858_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00153-y","volume":"8","author":"X Liu","year":"2017","unstructured":"Liu, X., Braun, G. B., Qin, M., Ruoslahti, E. & Sugahara, K. N. In vivo cation exchange in quantum dots for tumor-specific imaging. Nat. Commun. 8, 343 (2017).","journal-title":"Nat. Commun."},{"key":"21858_CR34","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1158\/1535-7163.MCT-17-1090","volume":"17","author":"JH Lo","year":"2018","unstructured":"Lo, J. H. et al. iRGD-guided tumor-penetrating nanocomplexes for therapeutic siRNA delivery to pancreatic cancer. Mol. Cancer Ther. 17, 2377\u20132388 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"21858_CR35","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1126\/science.1183057","volume":"328","author":"KN Sugahara","year":"2010","unstructured":"Sugahara, K. N. et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328, 1031\u20131035 (2010).","journal-title":"Science"},{"key":"21858_CR36","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","volume":"29","author":"DD Von Hoff","year":"2011","unstructured":"Von Hoff, D. D. et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J. Clin. Oncol. 29, 4548\u20134554 (2011).","journal-title":"J. Clin. Oncol."},{"key":"21858_CR37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","volume":"170","author":"DA Yardley","year":"2013","unstructured":"Yardley, D. A. nab-Paclitaxel mechanisms of action and delivery. J. Control. Release 170, 365\u2013372 (2013).","journal-title":"J. Control. Release"},{"key":"21858_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5904","volume":"5","author":"HB Pang","year":"2014","unstructured":"Pang, H. B. et al. An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability. Nat. Commun. 5, 4904 (2014).","journal-title":"Nat. Commun."},{"key":"21858_CR39","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/35046549","volume":"2","author":"ML Albert","year":"2000","unstructured":"Albert, M. L., Kim, J. I. & Birge, R. B. alphavbeta5 integrin recruits the CrkII-Dock180-rac1 complex for phagocytosis of apoptotic cells. Nat. Cell Biol. 2, 899\u2013905 (2000).","journal-title":"Nat. Cell Biol."},{"key":"21858_CR40","doi-asserted-by":"publisher","first-page":"11875","DOI":"10.1073\/pnas.1301766110","volume":"110","author":"TA Masters","year":"2013","unstructured":"Masters, T. A., Pontes, B., Viasnoff, V., Li, Y. & Gauthier, N. C. Plasma membrane tension orchestrates membrane trafficking, cytoskeletal remodeling, and biochemical signaling during phagocytosis. Proc. Natl Acad. Sci. USA 110, 11875\u201311880 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21858_CR41","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1152\/physiol.00028.2007","volume":"22","author":"KK Huynh","year":"2007","unstructured":"Huynh, K. K., Kay, J. G., Stow, J. L. & Grinstein, S. Fusion, fission, and secretion during phagocytosis. Physiology 22, 366\u2013372 (2007).","journal-title":"Physiology"},{"key":"21858_CR42","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1038\/onc.2012.320","volume":"32","author":"A Bianchi-Smiraglia","year":"2013","unstructured":"Bianchi-Smiraglia, A., Paesante, S. & Bakin, A. V. Integrin beta5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways. Oncogene 32, 3049\u20133058 (2013).","journal-title":"Oncogene"},{"key":"21858_CR43","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.1074\/jbc.C114.617662","volume":"290","author":"C Fedele","year":"2015","unstructured":"Fedele, C., Singh, A., Zerlanko, B. J., Iozzo, R. V. & Languino, L. R. The alphavbeta6 integrin is transferred intercellularly via exosomes. J. Biol. Chem. 290, 4545\u20134551 (2015).","journal-title":"J. Biol. Chem."},{"key":"21858_CR44","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1161\/01.RES.0000046017.96083.34","volume":"91","author":"U Kintscher","year":"2002","unstructured":"Kintscher, U. et al. PPARalpha inhibits TGF-beta-induced beta5 integrin transcription in vascular smooth muscle cells by interacting with Smad4. Circ. Res. 91, e35\u2013e44 (2002).","journal-title":"Circ. Res"},{"key":"21858_CR45","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/PPO.0b013e31827ab4c4","volume":"18","author":"CB Westphalen","year":"2012","unstructured":"Westphalen, C. B. & Olive, K. P. Genetically engineered mouse models of pancreatic cancer. Cancer J. 18, 502\u2013510 (2012).","journal-title":"Cancer J."},{"key":"21858_CR46","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1089\/ten.tea.2007.0434","volume":"15","author":"TT Chang","year":"2009","unstructured":"Chang, T. T. & Hughes-Fulford, M. Monolayer and spheroid culture of human liver hepatocellular carcinoma cell line cells demonstrate distinct global gene expression patterns and functional phenotypes. Tissue Eng. Part A 15, 559\u2013567 (2009).","journal-title":"Tissue Eng. Part A"},{"key":"21858_CR47","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.3892\/or.2016.4581","volume":"35","author":"M Schmidt","year":"2016","unstructured":"Schmidt, M., Scholz, C. J., Polednik, C. & Roller, J. Spheroid-based 3-dimensional culture models: gene expression and functionality in head and neck cancer. Oncol. Rep. 35, 2431\u20132440 (2016).","journal-title":"Oncol. Rep."},{"key":"21858_CR48","doi-asserted-by":"publisher","first-page":"e1014757","DOI":"10.1080\/23723556.2015.1014757","volume":"3","author":"SF Boj","year":"2016","unstructured":"Boj, S. F. et al. Model organoids provide new research opportunities for ductal pancreatic cancer. Mol. Cell. Oncol. 3, e1014757 (2016).","journal-title":"Mol. Cell. Oncol."},{"key":"21858_CR49","doi-asserted-by":"crossref","unstructured":"Dean, A., et al. Phase I trial of the first-in-class agent CEND-1 in combination with gemcitabine and nab paclitaxel in patients with metastatic pancreatic cancer. ESMO Virtual Congr. 2020 abstr. 1528P (2020).","DOI":"10.1016\/j.annonc.2020.08.2011"},{"key":"21858_CR50","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med"},{"key":"21858_CR51","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1535-6108(03)00309-X","volume":"4","author":"SR Hingorani","year":"2003","unstructured":"Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437\u2013450 (2003).","journal-title":"Cancer Cell"},{"key":"21858_CR52","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.1038\/s41388-019-0811-9","volume":"38","author":"ML Babicky","year":"2019","unstructured":"Babicky, M. L. et al. MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages. Oncogene 38, 5599\u20135611 (2019).","journal-title":"Oncogene"},{"key":"21858_CR53","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature14581","volume":"523","author":"SA Melo","year":"2015","unstructured":"Melo, S. A. et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523, 177\u2013182 (2015).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21858-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21858-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21858-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T11:08:49Z","timestamp":1669979329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21858-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["21858"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-21858-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]},"assertion":[{"value":"21 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.N.S., V.R.K., T.T., and E.R. have ownership interest (including patents) in Cend Therapeutics Inc. K.N.S., T.T., and E.R. are also co-founders and stockholders of Cend Therapeutics Inc. E.R. is the chairman of the board of Cend Therapeutics Inc. No potential conflicts of interest were disclosed by the other authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1541"}}